$LPAA News

Launch One Acquisition's Shareholders Approve Extension Of Business Combination Deadline To January 15, 2027

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Granted Two New U.S. Patents For Its IP Portfolio

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

FDA Grants Orphan Drug Designation To Minovia Therapeutic's Lead Investigational Compound, MNV-201 For Myelodysplastic Syndrome

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth

Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome

Minovia Therapeutics' MNV-201 Receives FDA Fast Track And Rare Pediatric Disease Designations For Pearson Syndrome Treatment

Sector Update: Financial Stocks Ease Late Afternoon

Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets

Minovia Therapeutics To Go Public Via Merger With Launch One Acquisition Corp., Forming Mito US One Ltd. To Advance Mitochondrial Therapies